A careful comparison, not a recommendation
Safety Scorecard
A data-first method for comparing ibogaine treatment settings through the safety information that can be documented, dated, and checked.
Evidence, uncertainty, and missing information stay visible.
What the score is designed to examine
Ibogaine has known cardiac risk considerations. The FDA drug-development framework illustrates why a treatment setting’s screening, monitoring, and response plan deserve separate attention from marketing claims.
This page treats a score as a record of disclosed safeguards, not proof of safety. It is intended to support the practical questions gathered across Bright Basin 16’s safety guidance and to help families distinguish a stated protocol from a verifiable one.
Public descriptions of best ibogaine treatment centers often vary in detail. A score can only reflect material that identifies what is screened, monitored, documented, and updated.
- Cardiac screeningWhether screening requirements, exclusions, ECG use, and medication review are documented.
- Emergency capacityWhether on-site response resources and hospital-transfer arrangements are described clearly.
- Monitoring & staffWhether continuous monitoring equipment and clinical oversight are specified in public materials.
- Event recordsWhether adverse events, mortality information, and limits on disclosure are addressed.
- Medical protocolWhether pre-treatment, observation, discharge, and follow-up procedures are available to review.
- Dosing variantWhether split dosing, microdosing, or other protocol choices are named and contextualized.
Torn-paper proof card
Current comparison register
There is no responsible basis here to publish named clinic rankings without a complete, dated, independently checkable evidence file for each setting. The table therefore records the present comparison state rather than assigning unsupported numbers. Questions about where ibogaine treatment may be available should remain separate from judgments about the adequacy of disclosed safety practices.
| Clinic name | Country | Score breakdown | Last data update |
|---|---|---|---|
| Named listings withheld pending source verification | Not assigned | Not scored — no complete, comparable documentation set verified for publication. | September 13, 2026 |
Scoring rule: a numeric total is withheld when any core criterion lacks dated primary documentation. This avoids converting absent evidence into an appearance of low or high performance.
The records behind a safety comparison
Where available, review should begin with direct clinic documentation and then look for public reports, peer-reviewed studies, or regulatory material that can clarify the context. The PubMed record for ibogaine research is useful for locating literature, but it does not verify the current practices of an individual treatment setting.
Terms can also obscure what is being discussed. For example, a discussion of an ibogaine street name is not evidence of clinical protocol, and stated ibogaine therapy benefits do not substitute for a documented medical screening process.
A setting’s account of pretreatment and post-treatment care should identify what happens before dosing, during observation, and after discharge. Materials concerning ibogaine treatment for depression require the same caution: they cannot establish individual appropriateness or replace individualized professional assessment.
Hand-drawn review path
How a score becomes publishable
Each review begins with a source trail, not a clinic claim. This is especially important where accounts of an ibogaine trip report describe personal experience but do not document a setting’s full emergency, staffing, or monitoring plan.
Limits that belong beside every score
A public score cannot confirm current conditions, individual medical suitability, or unreported events. It also cannot infer quality from cost, location, or an attractive account of care. Discussions of ibogaine treatment in Arizona, for example, need separate review of the legal and medical context where care is actually offered.
Ibogaine’s status differs across jurisdictions; the public overview of ibogaine notes its association with safety concerns and differing legal treatment. Jurisdiction alone does not establish the quality of a protocol.
Evidence can age quickly. A score is updated only when a new dated source clarifies a criterion, corrects a prior record, or reveals that information once available is no longer current. Cost pages such as ibogaine treatment cost information in Mexico may help a reader understand expenses, but they are not a safety record.
Questions worth keeping open
Reading the scorecard
For context on how this independent resource handles scope and uncertainty, see the explanation of our stated principles. The emphasis here remains on what can be documented about safety, not on endorsements.
Why are there no ranked clinic names in the table?
A comparative score should not be presented where direct documentation is incomplete or cannot be independently verified. The current table is a transparent evidence register rather than a recommendation list.
What changes a score?
A score can change when dated public documentation clarifies screening, emergency transfer arrangements, monitoring, medical protocol, adverse-event reporting, or dosing practices. New information is assessed against the same criteria rather than against promotional language.
Can a published score establish safety?
No. A score only describes the documentation reviewed against stated criteria. It cannot establish individual suitability, current operating conditions, or clinical outcomes. Questions about what help is offered are better understood alongside the resource’s practical evaluation tools.